Georgia Health Sciences University - Cancer Center - Cancer Clinical Research Unit (CCRU) -

Cancer Clinical Research Unit (CCRU)

Specialized Teams
Blood Cancers Farrukh T. Awan, MBBS	Bone Marrow Transplant Anand Jillella, MBBS
Breast Thomas Samuel, MD	Chest and Lung Zhonglin Hao, MD, PhD
Gastrointestinal Asha Nayak, MBBS	Genitourinary/Prostate Teresa A. Coleman, MD
Head and Neck Lana Jackson, MD	Gynecologic Sharad Ghamande, MBBS, MD
Skin Amanda May, MD

Phase I/II, open-label, dose escalation trial to evaluate the safety, Pharmacokinetics, and Pharmacodynamics of RAF265 (CHIR-265) administered orally to patients with locally advanced or Metastatic Melanoma
Phase I/B, open-label, multi-center, dose-escalation study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza®) in adult patients with MDS, CMML, or AML
Phase I study investigating the safety, tolerability, and pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) in patients with Advanced Solid Tumors
Phase I/IB study of TRU-016 in patients with Chronic Lymphocytic Leukemia or select subtypes of Non-Hodgkin’s Lymphoma
Phase I dose-escalation study of the safety and pharmacokinetics of XL147 administered orally daily to subjects with Solid Tumors or Lymphoma
Phase II, multi-center, open-label, exploratory study of Bcr-Abl kinetics in adult patients on nilotinib with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) and a suboptimal molecular response to imatinib
Phase II open-label, single-arm study of RAD001 in patients with mantle cell lymphoma who are refractory or intolerant to Velcade (bortezomib)
Phase II open-label, multicenter study to compare the efficacy and safety of RAD001 as first-line followed by second-line Sunitinib vs Sunitinib as first-line followed by second-line RAD001 in the treatment of patients with Metastatic Renal Cell Carcinoma
Phase II, single arm, open-label study to determine the efficacy of 100mg twice daily oral dosing of Midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease
Phase II trial of oral Panobinostat (LBH589), a novel deacetylase Inhibitor (DACi) in patients with Primary Myelofibrosis (PMF), Post Essential Thrombocythemia (ET) Myelofibrosis and Post-Polycythemia Vera (PV) Myelofibrosis
Phase II, multi-center, single arm, open label study of Panobinostat in combination with Bortezomib and Dexamethasone in patients with Relapsed and Bortezomib-Refractory Multiple Myeloma
Phase II study of XL147 in subjects with Advanced or Recurrent Endometrial Carcinoma
Phase II randomized discontinuation study of XL184 in subjects with Advanced Solid Tumors
Phase II study of oral Panobinostat in adult patients with Relapsed/Refractory Classical Hodgkin's Lymphoma after failure of high-dose chemotherapy with Autologous Stem Cell Transfusion and a Gemcitabine- or Vinorelbine- or Vinblastine- containing treatment regimen
Phase III, randomized, double-blind trial to compare the efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer

Learn about patient experiences in clinical trials:

Walter E. Stuckley

Ralph Brown

Jimmy Burgamy

Raymond Taylor

Advancing developmental therapeutics drives an enterprise such as the GHSU Cancer Center. The center is organized into three broad groups of investigators:

basic scientists, who compare normal and abnormal cells, identifying and validating targets for drug intervention in vitro and in animal models;
translational researchers, who find new investigational drugs and design human trials;
clinical researchers, who conduct Phase I, II and III trials with patients.

The basic science portfolio for developmental therapeutics includes genomics / epigenomics, molecular signaling, immunotherapy and chaperone biology. Clinical researchers include surgical oncologists, medical / hormonal oncologists and radiation oncologists. Translational researchers are the bridge between the two.

Share|

GHSU Cancer Center

GHSU Cancer Center
1410 Laney Walker Blvd.
Augusta, GA 30912

706-721-1660 office
706-721-0469 fax

Cancer Team
cancer@ georgiahealth.edu

Cancer Clinical Research Unit (CCRU)

Specialized Teams

Cancer Clinical Research Unit

Cancer Center Main Menu